Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer

Table 1 Patient characteristics at baseline

Characteristics	No. of patients	%
Age, yr
Median	64
Range	34-84
Age, category
< 50 yr	5	9.8
50-59 yr	8	15.7
60-69 yr	22	43.1
70-79 yr	15	29.4
> 80 yr	1	2
Sex
Male	36	70.6
Female	15	29.4
WHO performance status1
0	37	72.5
1	13	25.5
2	1	2
Clinical T stage2
T1	5	9.8
T2	12	23.5
T3	21	41.2
T4	2	3.9
Unknown	11	21.6
Clinical N stage2
N0	16	31.4
N1	19	37.3
N2	4	7.8
N3	2	3.9
Unknown	10	19.6

¹WHO: World Health Organization;

²TNM classification.

Table 2 Feasibility: Treatment cycles delivered

	No. of patients	%
Cycles received
1	51	100
2	44	86.3
3	39	76.5
4	35	68.6
Percentage of intended dose delivered (per evaluable patient, ITT)1
Docetaxel		78.90
Cisplatin		78.70
Capecitabine		78.30
Percentage of intended dose delivered in patients receiving 4 courses (n = 34)
Docetaxel		92.90
Cisplatin		92.90
Capecitabine		91.60

¹ITT: Percentage of dose delivered of all four courses divided by the amount of patients who could have received the full course.

Table 3 Grade 3-4 adverse events related to chemotherapy

Toxicity	No of patients	%	No of cycles	%
Hematologic
Anemia	3	5.9	3	1.8
Neutropenia	25	49	32	18.9
Febrile neutropenia	16	31.4	17	10.1
Non-Hematologic
Gastro-intestinal
Anorexie	8	15.7	10	5.9
Constipation	1	2	1	0.6
Diarrhea	13	25.5	16	9.5
Dysphagia	1	2	1	0.6
Mucositis	6	11.8	6	3.6
Nausea	5	9.8	5	2.9
Vomiting	5	9.8	8	4.7
Constitutional
Fatigue	4	7.8	4	2.4
Hand-foot syndrome	4	7.8	6	3.6
Neurosensory
Hearing impairment	1	2	1	0.6
Neuropathy	2	3.6	2	1.2
Renal impairment	3	5.9	3	1.8